Radiopharm Theranostics Completes Enrollment in Phase 2b Trial for Brain Metastases Diagnostic RAD 101
Summary
Radiopharm Theranostics has completed patient enrollment in its U.S. Phase 2b imaging trial for RAD 101, a diagnostic for recurrent brain metastases, with full data readout expected in June 2026.
Key Events
-
Phase 2b Enrollment Completed
Radiopharm Theranostics has completed patient enrollment in its U.S. Phase 2b imaging trial (NCT06777433) for RAD 101, a diagnostic for recurrent brain metastases.
-
Positive Interim Data Reported
Interim results from the trial showed 90% concordance with MRI, the primary endpoint, reinforcing confidence in RAD 101's potential.
-
Full Data Readout and Phase 3 Plans
The full clinical trial data readout is anticipated in June 2026, with the company planning to advance RAD 101 into a U.S. Phase 3 pivotal trial.
-
FDA Fast Track Designation
RAD 101 previously received FDA Fast Track Designation for distinguishing recurrent disease from treatment effect of brain metastases.
Analysis
The completion of enrollment in the Phase 2b trial for RAD 101 marks a significant clinical milestone for Radiopharm Theranostics. This diagnostic candidate, which targets fatty acid synthase (FASN) and has FDA Fast Track Designation, showed 90% concordance with MRI in interim data. The company's plan to advance RAD 101 into a Phase 3 pivotal trial, following the expected full data readout in June, indicates strong confidence in its potential to address a critical unmet need in detecting brain metastases. This progress could significantly de-risk the program and represents a positive step towards potential commercialization for the small-cap biotech.
At the time of this filing, RADX was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.4M. The 52-week trading range was $3.62 to $16.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.